Mar 16, 2026
Summary The current treatment landscape for underactive bladder largely depends on pharmacological management and catheterization. Despite the significant unmet need, the clinical development pipeline for UAB remains relatively sparse. Notable candidates include TAC-302, being developed by Taiho Pharmace...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper